EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study

Ming Lin, Bowen Gao, Mengnan Peng, Xuefang Chen, Huanming Xiao, Meijie Shi, Xiujuan Zhang, Folai Zeng, Xiaoling Chi

Frontiers in Physiology · 09.02.2024 · 15

DOI: 10.3389/fphys.2024.1347459 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Physiology, online erschienen am 09.02.2024. Verfasst von Ming Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medici…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combined effect of hepatitis B virus infection and metabolic dysfunction-associated steatotic liver disease (MASLD) on hepatocellular carcinoma (HCC) risk remains unclear. The current study sought to elucidate the impact of MASLD on HCC progression in chronic hepatitis B (CHB) patients.

Method

This retrospective cohort study included CHB patients who had undergone liver biopsy and abdominal imaging at the Guangdong Provincial Hospital of Chinese Medicine between 2013 and 2019. We investigated the correlation between MASLD and HCC risk, and inverse probability treatment weighting (IPTW) was used to adjust for patient characteristics.

Results

A total of 1,613 patients were included, and 483 (29.9%) were diagnosed with MASLD. Over a median follow-up period of 5.02 years, 36 (2.2%) developed HCC, comprising 4.8% (23/483) of those with MASLD and 1.2% (13/1,130) of those without. Those with MASLD had a significantly higher cumulative incidence of HCC than those without ( p < 0.001). The presence of MASLD was associated with a higher risk of HCC (adjusted hazard ratio [HR], 3.996; 95% confidence interval [CI], 2.007–7.959; p < 0.001). After adjustment using IPTW, the patients with MASLD retained a higher cumulative incidence of HCC ( p < 0.001). Moreover, MASLD was found to be an independent risk factor for the development of HCC (adjusted HR, 10.191; 95% CI, 4.327–24.002; p < 0.001). However, among patients with MASLD, there were no significant differences in the cumulative risk of HCC between patients with and without overweight, between those with <2 and ≥2 cardiometabolic risk factors (CMRFs), between those with <3 and ≥3 CMRFs, or between those with <4 and ≥4 CMRFs ( p = 0.110, p = 0.087, p = 0.066, and p = 0.490, respectively).

Conclusion

The presence of MASLD is associated with a higher risk of HCC in patients with CHB. Notably, this higher risk is present in patients with MASLD, irrespective of the presence or absence of overweight or the number of CMRFs they have.

Schlagwörter

Stichwörter der Autor:innen

hepatic steatosishepatitis Bhepatocellular carcinomainverse probability treatment weightingmetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Hepatology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Community Health Service Center of Tianhenan Street Tianhe District, Guangzhou, China.
  • Department of Hepatobiliary Surgery, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Zitieren

APA

Lin, M., Gao, B., Peng, M., Chen, X., Xiao, H., Shi, M., Zhang, X., Zeng, F., & Chi, X. (2024). Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study. Frontiers in Physiology, 15. https://doi.org/10.3389/fphys.2024.1347459

Vancouver

Lin M, Gao B, Peng M, Chen X, Xiao H, Shi M, et al. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study. Frontiers in Physiology. 2024;15. doi:10.3389/fphys.2024.1347459

BibTeX
@article{Lin2024,
  author = {Lin, Ming and Gao, Bowen and Peng, Mengnan and Chen, Xuefang and Xiao, Huanming and Shi, Meijie and Zhang, Xiujuan and Zeng, Folai and Chi, Xiaoling},
  title = {Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study},
  journal = {Frontiers in Physiology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphys.2024.1347459}
}
Kostenlos starten →